CA3039681A1 - Composition comprising thylakoid extract for use in the prevention and/or treatment of cardiovascular diseases - Google Patents

Composition comprising thylakoid extract for use in the prevention and/or treatment of cardiovascular diseases Download PDF

Info

Publication number
CA3039681A1
CA3039681A1 CA3039681A CA3039681A CA3039681A1 CA 3039681 A1 CA3039681 A1 CA 3039681A1 CA 3039681 A CA3039681 A CA 3039681A CA 3039681 A CA3039681 A CA 3039681A CA 3039681 A1 CA3039681 A1 CA 3039681A1
Authority
CA
Canada
Prior art keywords
extract
composition
subject
thylakoid
heart disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3039681A
Other languages
English (en)
French (fr)
Inventor
Andre P. Boulet
Theophilus J. Gana
Nathalie Boucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Groupe Sante Devonian Inc
Original Assignee
Groupe Sante Devonian Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Groupe Sante Devonian Inc filed Critical Groupe Sante Devonian Inc
Publication of CA3039681A1 publication Critical patent/CA3039681A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3039681A 2016-11-04 2017-11-03 Composition comprising thylakoid extract for use in the prevention and/or treatment of cardiovascular diseases Pending CA3039681A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417415P 2016-11-04 2016-11-04
US62/417,415 2016-11-04
PCT/CA2017/051306 WO2018081903A1 (en) 2016-11-04 2017-11-03 Composition for the prevention and/or treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
CA3039681A1 true CA3039681A1 (en) 2018-05-11

Family

ID=62076517

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3039681A Pending CA3039681A1 (en) 2016-11-04 2017-11-03 Composition comprising thylakoid extract for use in the prevention and/or treatment of cardiovascular diseases

Country Status (5)

Country Link
US (1) US11033592B2 (cg-RX-API-DMAC7.html)
EP (1) EP3534924A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019533691A (cg-RX-API-DMAC7.html)
CA (1) CA3039681A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018081903A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230056443A1 (en) * 2021-08-21 2023-02-23 Nathalie Boucher Equine gastric health formulation
CN115786246B (zh) * 2022-12-16 2024-09-06 四川轻化工大学 斑马鱼免疫无应答性心力衰竭模型的构建方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293852A1 (fr) 1999-12-30 2001-06-30 Purecell Technologies Inc. Procede de preparation d'extraits de plantes actifs et utiles a la capture de radicaux libres; les extraits, et compositions et dispositifs les comprenant
WO2003004042A1 (en) * 2001-07-02 2003-01-16 Purecell Technologies Inc. Compositions comprising thylakoids useful in the modulation of the inflammation process
EP1663268B1 (en) 2003-09-22 2013-05-08 Purecell Technologies Inc. Oral compositions and route of administration for the delivery of a thylakoid extract
EP2320919B1 (en) * 2008-07-14 2016-03-30 Thylabisco Ab Large-scale process for the preparation of thylakoids

Also Published As

Publication number Publication date
JP2019533691A (ja) 2019-11-21
WO2018081903A1 (en) 2018-05-11
EP3534924A4 (en) 2020-07-01
US20190314433A1 (en) 2019-10-17
US11033592B2 (en) 2021-06-15
EP3534924A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
Jensen et al. In vitro and in vivo antioxidant and anti-inflammatory capacities of an antioxidant-rich fruit and berry juice blend. Results of a pilot and randomized, double-blinded, placebo-controlled, crossover study
Agbor et al. Antioxidant and anti-atherogenic activities of three Piper species on atherogenic diet fed hamsters
Deharo et al. In vitro immunomodulatory activity of plants used by the Tacana ethnic group in Bolivia
Yang et al. Effect of astaxanthin on metabolic cataract in rats with type 1 diabetes mellitus
IT202100001343A1 (it) Nanovescicole derivanti da vegetali biologici come trasportatori naturali di fitocomplessi ad uso nutraceutico, cosmetico e rigenerativo
Bueno et al. Protective effect of dietary polysaccharides from yellow passion fruit peel on DSS‐induced colitis in mice
Bernardes et al. Sesquiterpene lactones from Lychnophora species: antinociceptive, anti-inflammatory, and antioxidant pathways to treat acute gout
US11033592B2 (en) Composition for the prevention and/or treatment of cardiovascular diseases
CN109661238A (zh) 治疗红细胞疾病的治疗组合
Verdam et al. Anti-inflammatory action of Justicia acuminatissima leaves
Librandi et al. Effect of the extract of the tamarind (Tamarindus indica) fruit on the complement system: studies in vitro and in hamsters submitted to a cholesterol-enriched diet
CN121128806A (zh) 一种辅助改善阿尔茨海默症蛋白质粉及其制备方法
US11723938B2 (en) Thylakoid extract composition and formulation for the treatment of inflammatory bowel disease
García-Rodríguez et al. Anti-inflammatory evaluation and antioxidant potential of Senna crotalarioides and Penstemon roseus
US8445040B2 (en) Extracts of Sclerocarya birrea
Ndem et al. Assessing the effect of concomitant administration of artemether-lumefantrine and ciprofloxacin on some cardiac parameters in Wistar rats:“The remedial role of vitamin E”
Rossato et al. Safety profile, antimicrobial and antibiofilm activities of a nanostructured lipid carrier containing oil and butter from Astrocaryum vulgare: in vitro studies
US20180370891A1 (en) Curcumin compositions for improvement in cardiovascular flow
JP2019210278A (ja) コレステロール低減用組成物及びコレステロール低減機能性付与方法
TWI918004B (zh) 用於預防、改善及／或治療肌肉疾病或肌肉失調之組合
Myers et al. A forced titration study of the antioxidant and immunomodulatory effects of Ambrotose AO supplement
Innih et al. Anti-hyperlipidemic effect of date palm on hyperlipidemia in rats
US20150328272A1 (en) Compositions for Improving the Development of Arteriosclerotic Vascular Diseases
Eteraf-Oskouei et al. The Effects of Solvent Fractions of Bee Pollen Crude Extract in an Animal Model of Inflammation
Umair et al. In vivo Anti-hyperlipidemic Potential of Chloroform Extract of Fagonia indica in Streptozotocin-induced Rats

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220825